TransMedics Group: I've been waiting for the stabilization of growth rates
By 2028, 10,000 transplantations are expected to be supported annually
Thanks to US production, tariffs currently have minimal impact
Reading Time: 1 minute
The stock of TransMedics Group (TMDX) is setting new standards in organ transplantation with the Organ Care System (OCS), improving the quality, utilization rate, and transport range of livers, lungs, and hearts. I see a good chance that the bottom formation can now be completed. The growth rates have gradually slowed down in recent quarters from about 118% to nearly 64%, and then down to almost 50%. A stabilization is evident with an increase from 48.2% to $143.5 million (consensus: $123.7 million). Moreover, net profit was doubled to $0.70...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
